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The 2014/15 influenza season was the second season 
of roll-out of a live attenuated influenza vaccine (LAIV) 
programme for healthy children in England. During 
this season, besides offering LAIV to all two to four 
year olds, several areas piloted vaccination of primary 
(4–11 years) and secondary (11–13 years) age children. 
Influenza A(H3N2) circulated, with strains genetically 
and antigenically distinct from the 2014/15 A(H3N2) 
vaccine strain, followed by a drifted B strain. We 
assessed the overall and indirect impact of vaccinat-
ing school age children, comparing cumulative disease 
incidence in targeted and non-targeted age groups in 
vaccine pilot to non-pilot areas. Uptake levels were 
56.8% and 49.8% in primary and secondary school 
pilot areas respectively. In primary school age pilot 
areas, cumulative primary care influenza-like con-
sultation, emergency department respiratory attend-
ance, respiratory swab positivity, hospitalisation and 
excess respiratory mortality were consistently lower 
in targeted and non-targeted age groups, though less 
for adults and more severe end-points, compared with 
non-pilot areas. There was no significant reduction for 
excess all-cause mortality. Little impact was seen in 
secondary school age pilot only areas compared with 
non-pilot areas. Vaccination of healthy primary school 
age children resulted in population-level impact 
despite circulation of drifted A and B influenza strains.
Background
The United Kingdom (UK) started the phased introduc-
tion of a universal childhood influenza vaccination pro-
gramme in the 2013/14 influenza season following the 
recommendation of the Joint Committee on Vaccination 
and Immunisation (JCVI) that all healthy children 
aged two to less than 17 years should be offered the 
newly licensed live attenuated influenza vaccine 
(LAIV) [1]. The decision was informed by transmission 
modelling using Bayesian evidence synthesis, which 
predicted that vaccination of healthy children would 
provide direct protection to the vaccinated children 
themselves and by reducing infection in this group, it 
would decrease transmission of influenza in the gen-
eral population and thus provide indirect protection 
to groups at higher risk of severe disease such as the 
elderly and those with underlying clinical risk factors 
[2]. Although North America has a long-standing child-
hood influenza vaccination programme, there is only 
limited published observational evidence of whether 
such programmes produce such indirect population 
effects [3-5]. Questions also remain as to which paedi-
atric age-groups to target to achieve optimal direct and 
indirect protection; is it preferable to either vaccinate 
all school age children or to focus on certain groups 
such as primary school age children alone?
In the first year of the LAIV programme in England, all 
healthy children aged two to three years were offered 
a single dose of LAIV, together with children of primary 
school age (4–11 years) in a series of geographically 
discrete pilot areas. Early results suggested that vac-
cinating primary school age children led to population-
level reductions for a range of influenza indicators in 
pilot areas compared with non-pilot areas [6]. These 
results, however, were not significant, likely due to the 
low intensity of virus circulation in the 2013/14 influ-
enza season and the relatively limited number of pri-
mary school age children vaccinated.
In 2014/15, the national LAIV programme was extended 
to all two to four year-olds in England [7]. In addi-
tion, the primary school age pilots continued with an 
increase in the size of the target populations where 
healthy children 4 to 11 years of age were offered a dose 
of LAIV, together with the recruitment of additional 
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pilot areas where healthy secondary school children 
aged 11 to 13 years were offered LAIV. A range of deliv-
ery models were deployed specifically school-based 
or within the community via pharmacies and primary 
care. The 2014/15 influenza season was a moderately 
intense season dominated initially by the circulation 
of influenza A(H3N2) virus, which usually results in 
severe disease in the elderly, followed by influenza B 
virus [8]. Virological surveillance found that, as seen 
elsewhere, the dominant circulating influenza A(H3N2) 
and B strains were antigenically and genetically drifted 
against the relevant components of the 2014/15 sea-
sonal influenza vaccine for the northern hemisphere 
[9].
The implementation of the primary and secondary 
school age pilots provided a unique opportunity to 
assess the level of population protection that vaccinat-
ing school age children with LAIV might provide over 
and above the vaccination of pre-school age children 
in a season when drifted strains circulated. The aim 
of this paper is thus to measure the uptake of the pro-
gramme and evaluate the total and indirect impact of 
vaccinating healthy children of primary or secondary 
school age in England in 2014/15.
Methods
Most areas that undertook vaccination of primary 
school age children in the 2013/14 season (6/7) 
decided to continue this activity in 2014/15 [6]. Local 
National Health Service (NHS) England teams with an 
interest in running secondary school age pilot influ-
enza immunisation programmes were selected by the 
national team. Different models of delivery, in par-
ticular, school-based and community-based through 
pharmacy and primary care, were undertaken in these 
pilots. Most were school-based, with the exception of 
two area teams following a pharmacy-based model 
and one local team following a community GP delivery 
model.
Measuring vaccine uptake
The target population for delivery was defined as 
children of primary school age (born between 2 Sep 
2003 and 1 Sep 2010; 4 to 11 years old) resident in six 
pilot areas in England: Cumbria, Greater Manchester, 
Leicestershire and Lincolnshire, London and Essex, 
Northumberland, Tyne and Wear. The target population 
for children of secondary school age (born between 
2 Sep 2001 and 1 Sep 2003; 11–13 years of age) were 
children resident in 12 selected pilot areas (Arden, 
Birmingham and Black Country, Greater Manchester, 
East Anglia, Essex, Herefordshire and Worcestershire, 
Lancashire, London, North Yorkshire and Humber, 
Shropshire and Staffordshire, South Yorkshire and 
Bassetlaw, West Yorkshire). Four of the latter sites also 
ran primary school age programmes. The geographical 
distribution of these sites is shown in Figure 1.
Local NHS teams responsible for the delivery of the LAIV 
programme in pilot areas gathered and reported data on 
vaccine administration to Public Health England (PHE) 
using a standard proforma through a web-based por-
tal. End-of-season programme uptake was calculated 
based on the number of children in the target popula-
tion who were reported to have received at least one 
dose of influenza vaccine during the campaign period 
(September 2014 until January 2015). Healthy children 
and at-risk children in whom the vaccine was not con-
traindicated were offered LAIV. Inactivated influenza 
vaccine was offered to at-risk children in whom LAIV 
was contraindicated.
Measuring school age vaccine programme 
impact
The study period for the programme impact calcula-
tions was from week 40 2014 until week 14 2015, the 
end of notable influenza transmission in the commu-
nity in the 2014/15 season [8].
LAIV programme impact was defined as the difference 
in cumulative disease incidence in school age pilots 
compared with non-pilot areas for the study period. 
Figure 1
Geographical distribution of school-age pilot areas, 
England, week 40 2014 to week 14 2015
primary school pilot
primary and secondary school pilot
secondary school only pilot
Contains Ordnance Survey data, Crown copyright and database 
right 2014.
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It was measured for a range of clinical and virological 
respiratory endpoints in primary and secondary care.
Primary school age only vaccine areas were pooled 
with primary and secondary school age vaccine areas 
to examine the impact of vaccinating primary school 
age children together with cohorts of two years of 
secondary school children in addition to the vaccina-
tion of pre-school age children. Secondary school age 
only pilot areas were compared with non-pilot areas to 
determine the impact of vaccinating the first two years 
of secondary school age children alone (i.e. in addition 
to vaccinating children two to four years of age).
Cumulative levels of activity in pilot versus non-pilot 
areas were compared for four age groups. To examine 
direct impact, the two targeted age groups for which 
surveillance data were available were primary school 
children (5–10 years old) and secondary school chil-
dren (11–16 years old, where children aged 11–13 years 
were offered vaccine). To examine indirect impact, the 
non-targeted age groups compared were under 5 years 
old and 17 years old and older. Overall impact was 
assessed by comparing the disease incidence for all 
ages in pilot vaccination areas compared with non-pilot 
areas. Indirect impact was measured by comparing 
incidence in non-targeted age groups in pilot relative 
to non-pilot areas. To ensure appropriate geographical 
coverage for the sentinel surveillance schemes, addi-
tional sites (general practitioners (GPs), emergency 
departments and hospitals) were recruited in primary 
and secondary pilot areas where required.
Data sources
A range of surveillance systems were used to measure 
the impact of the school age vaccination programme.
Primary care
Surveillance in primary care was undertaken through 
monitoring the weekly influenza-like-illness (ILI) con-
sultation rates through the Royal College of General 
Practitioners (RCGP) Research and Surveillance Centre 
(RSC) Weekly Returns Service sentinel GP network, 
with 29 general practices participating in pilot areas 
and 58 in non-pilot areas. A proportion of these prac-
tices, in conjunction with practices recruited through 
the PHE coordinated Sentinel Microbiology Network 
(SMN) scheme, undertook respiratory swabbing on 
patients under 18 years of age presenting with ILI, and 
a proportion of patients  18 years of age and older.
Secondary care
The UK Severe Influenza Sentinel Surveillance System 
(USISS sentinel) consists of a network of 30 NHS hos-
pital trusts (15 in pilot areas and 15 in non-pilot areas 
in 2014/15) who report the weekly number of labora-
tory-confirmed influenza hospital admissions [10]. 
Confirmed influenza hospitalisation rates by age group 
and pilot area were calculated using estimated hos-
pital catchment populations [11]. As age grouping of 
populations was not consistent with this analysis, age-
specific denominator data were estimated using popu-
lation age-distributions by Strategic Health Authority 
from the Office for National Statistics [12].
Figure 2
Uptake of primary and secondary school age influenza vaccination programme in pilot areas by type of delivery, England, 
week 40 2014 to week 14 2015
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Figure 3
Cumulative primary care indicators in primary school pilot, secondary school pilot and non-pilot areas, England, week 40 
2014 to week 14 2015
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Figure 4
Cumulative secondary care indicators in primary school pilot, secondary school pilot and non-pilot areas, England, week 40 
2014 to week 14 2015
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A mandatory scheme is also in operation in all NHS hos-
pitals across England (UK Severe Influenza Surveillance 
System (USISS mandatory)), monitoring all influenza 
confirmed intensive care unit (ICU) / high dependency 
unit (HDU) admissions. Rates were calculated by pilot 
type and age group as for USISS sentinel [11].
The Respiratory DataMart scheme (RDMS) reports all 
influenza reverse-transcription-polymerase chain reac-
tion (RT-PCR) respiratory swab results (both positive 
and negative) from a network of PHE and NHS labora-
tories in England, with the majority of samples (> 90%) 
taken from patients in secondary care [13]. Postcode 
of residence was used to allocate patients to pilot and 
non-pilot areas. Influenza swab positivity rates in pilot 
and non-pilot areas were compared by age group.
The Emergency Department Syndromic Surveillance 
System (EDSSS) monitors routine syndromic surveil-
lance data, in real-time, using anonymised emergency 
department attendances, across a sentinel network of 
emergency departments [14]. Attendances monitored 
include those for respiratory illness. The proportion of 
all EDSSS attendances for respiratory illness in pilot 
and non-pilot areas (three emergency departments in 
primary school age pilot areas, eight in secondary and 
18 in non-pilot areas) was compared by age group.
Excess mortality
Weekly excess mortality was estimated in pilot and 
non-pilot areas based on place of residence using rou-
tine death registration data from the Office for National 
Statistics. The European Monitoring of Excess Mortality 
for Public Health Action (EuroMOMO) standard algo-
rithm was used to calculate the number of deaths 
expected for a given week in the year [15]. The number 
Figure 5
Cumulative weekly all-cause and respiratory excess 
mortality in primary school pilot, secondary school only 
pilot and non-pilot areas, England, influenza season, week 
40 2014 to week 14 2015
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Figure 6
Cumulative, all-age influenza indicators in pilot and non-
pilot areas before (2010/11 and 2012/13) and after (2012/13 
and 2014/15) vaccine programme introduction, England
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of observed deaths (corrected for reporting delay) was 
compared with the modelled number expected each 
week to determine if statistically significant excess 
mortality was seen in pilot and non-pilot areas [16]. 
This was applied to all-cause deaths and deaths where 
the primary cause of death was coded as respiratory 
applying the International Classification of Disease ver-
sion 10 (ICD 10) code “J” [17]).
Statistical methods
For the RCGP, USISS sentinel and USISS mandatory 
schemes, cumulative disease incidence rates per 
100,000 population by age and pilot group were cal-
culated by summing the number of disease episodes 
each week from week 40 2014 to week 14 2015 relative 
to the average weekly population at risk, with exact 
Poisson confidence intervals (CIs) calculated.
For the RCGP swabbing and EDSSS schemes, cumula-
tive influenza swab positivity and proportion of emer-
gency department attendances coded as respiratory 
were calculated by age and pilot group by summing 
the number of positive samples/patients attending 
with respiratory symptoms and the number of samples 
tested each week/total number of attendances from 
week 40 2014 to week 14 2015 with exact binomial CIs 
calculated.
To determine the impact in primary and secondary 
school age pilot areas, odds ratios and corresponding 
95% CIs were calculated by age group and scheme, 
with non-pilot areas set as the reference group. Data 
were converted to binomial individual level across 
schemes and random effects logistic regression car-
ried out, adjusting for clustering at the level of report-
ing unit (e.g. GP, trust, laboratory).
For the all-cause and respiratory coded deaths, the dif-
ference between the observed and expected weekly 
deaths was summed from week 40 2014 to week 
14 2015 to obtain the cumulative number of excess 
deaths. Excess mortality rates were then calculated per 
100,000 population.
Laboratory methods
Influenza laboratory confirmation for samples from 
primary and secondary care was undertaken using 
RT-PCR assays capable of detecting circulating influ-
enza A viruses, influenza B viruses and other respira-
tory viruses. Samples in England were sent to the PHE 
Age group Measure
RCGP (per 100,000 population) Sentinel swab positivity (%)
Non-pilot Primarya Secondary Non-pilot Primarya Secondary
Primary 
school 
5–10 
years 
Rate/proportion 266.9 19.7 269.7 44.6 16.7 50
(n/N) (104/38,969) (1/5,086) (39/14,459) 37/83 1/6 17/34
Risk difference −247 3 −28 5
OR  
(95% CI) 
0.06  
(0.01 to 0.62) 
0.81 
(0.39 to 1.69)
0.25 
(0.03 to 2.22)
1.24 
(0.56 to 2.77)
p value 0.018 0.573 0.213 0.594
Secondary 
school 
11–16 
years 
Rate/proportion 371.22 112.6 447.1 41 18.2 38.6
(n/N) (133/35,830) (6/5,330) (64/14,315) 41/100 2/11 17/44
Risk difference −259 76 −23 −2
OR  
(95% CI) 
0.31  
(0.10 to 0.95) 
0.96 
(0.53 to 1.73)
0.32 
(0.07 to 1.56)
0.91 
(0.44 to 1.87)
p value 0.04 0.882 0.158 0.79
Other age 
groups 
 < 5 years
Rate/proportion 253.1 26.1 34.6 14 0 20
(n/N) (84/33,192) (1/3,826) (27/11,511) 21/150 0/7 8/40
Risk difference −227 −219 −14 6
OR  
(95% CI) 
0.08 
(0.01 to 1.02)
0.65 
(0.25 to 1.67) 1
1.54 
(0.62 to 3.78)
p value 0.052 0.367 NA 0.351
≥17 years 
Rate/proportion 508.1 219.1 446.6 29 18.5 26.7
(n/N) (2,299/452,461) (143/65,260) (767/171,735) 378/1,305 28/151 135/506
Risk difference -289 -62 −10 −2
OR  
(95% CI) 
0.41  
(0.19 to 0.86) 
0.67 
(0.42 to 1.07)
0.68 
(0.37 to 1.24)
1.23 
(0.72 to 2.11)
p value 0.018 0.092 0.206 0.455
Table 1
Impact of vaccinating primary and/or secondary school age children on selected primary care influenza surveillance 
indicators, England, influenza season, week 40 2014 to week 14 2015
CI: confidence interval; NA: not available; OR: odds ratio; RCGP: Royal College of General Practitioners.
a Includes primary and secondary school pilot areas.
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Microbiology Services, Colindale (RCGP scheme), one 
of the network of specialist PHE microbiology labora-
tories (SMN scheme) or NHS laboratories elsewhere in 
England.
Results
Uptake
The total target population for the pilots was estimated 
to be 346,962 primary school children and 371,109 for 
secondary school children aged 11 to13 years. Five of 
the six primary school pilot areas chose to deliver the 
programme through a school-based approach, while 
one, Cumbria, delivered through community pharma-
cies. Of the 12 secondary school pilots, 10 delivered 
the programme through schools only; one through 
community pharmacies and one through both schools 
and primary care.
An estimated 196,994 primary school age children 
received at least one dose of influenza vaccine result-
ing in an overall uptake of 56.8%. This ranged from 
32.3% to 63.1% at pilot-site level (Figure 2). An esti-
mated 184,975 secondary school age children received 
at least one dose of influenza vaccine, an overall 
uptake of 49.8%. Uptake ranged from 21.2% to 62.0% 
at pilot level (Figure 2).
In the primary school age programme, uptake in all the 
school-based areas was in excess of 50%, compared 
with coverage of around 30% in the area delivering 
the programme through a pharmacy-based model. 
These findings were mirrored by the secondary school 
age programme, where uptake through school-based 
models was close to or well in excess of 50%, with an 
uptake of less than 30% in the areas using community-
based delivery models (Figure 2).
Influenza vaccine uptake achieved through primary 
care in two to four year olds in primary school pilot 
areas only was 44.1% (224 practices) compared with 
39.4% (2,361 practices) in secondary school age vac-
cine pilot areas; 35.1% (1,012 practices) in primary and 
secondary school pilot areas and 38.1% (4,176 prac-
tices) in non-pilot areas.
Programme impact
Patterns of activity
The cumulative ILI consultation rate and swab posi-
tivity in primary care, emergency department respira-
tory attendances, cumulative hospitalisation incidence 
rate, RDMS influenza positivity and ICU/HDU rates from 
week 40 2014 to week 14 2015 were generally lower in 
pilot areas where primary school age children were 
vaccinated compared with non-pilot areas across both 
targeted and non-targeted age groups (Figures 3 and 
4). These differences were less marked for the cumula-
tive ICU/HDU and RDMS indicators, particularly in the 
older non-targeted age group (≥ 17 years of age).
A large excess all-cause and respiratory mortality was 
observed in both pilot and non-pilot areas. No signifi-
cant reduction in all-cause mortality was observed in 
primary school pilot areas compared with non-pilot 
areas for all ages, whereas a significant reduction was 
observed for respiratory excess mortality (Figure 5).
Overall when comparing the various cumulative influ-
enza indicators for secondary school pilot areas (11-13 
year olds vaccinated only) to non-pilot areas, no such 
differences were observed, in both targeted and non-
targeted age groups (Figures 3, 4 and 5).
Examination of pre-vaccination data for those indica-
tors for which data were available, provided a mixed 
pattern, with evidence of similar activity in primary 
school areas compared to others in one season, 
whereas it was lower in another (Figure 6).
Impact
Vaccinating primary school age children resulted in sig-
nificant reductions in cumulative incidence/laboratory-
confirmed positivity in the targeted age group (5–10 
years) in pilot compared with non-pilot areas for GP ILI 
consultations (94% reduction, p = 0.018); emergency 
department respiratory attendances (74% reduction, 
p = 0.035), confirmed influenza hospital admissions 
(93% reduction, p = 0.012); with non-significant 
reductions in GP swabbing positivity (75% reduction, 
p = 0.213), confirmed influenza ICU admissions (76% 
reduction, p = 0.271) and DataMart influenza positivity 
(42% reduction. p = 0.187) (Tables 1,2).
Vaccinating primary school age children also resulted 
in an indirect non-significant reduction in under five 
year-olds, in pilot compared with non-pilot areas, 
for GP ILI consultations (92% reduction, p = 0.052); 
emergency department respiratory attendances 
(65%, p = 0.33); confirmed influenza hospital admis-
sions (61% reduction, p = 0.128); confirmed influenza 
ICU/HDU admissions (61% reduction, p = 0.324) and 
DataMart influenza positivity (24%. p = 0.186) (Tables 
1 and 2).
Significant indirect reductions were also seen in indi-
viduals  ≥17 years of age when comparing GP ILI consul-
tations in primary school pilot to non-pilot areas (59% 
reduction, p = 0.018) and non-significant reductions 
in sentinel GP swabbing (32% reduction, p = 0.206); 
emergency department respiratory attendances (21% 
reduction, p = 0.518); influenza confirmed hospital 
admissions (34% reduction, p = 0.434); influenza con-
firmed ICU/HDU admissions (46% reduction, p = 0.115) 
and DataMart influenza positivity (9% reduction; 
p = 0.327)(Tables 1 and 2).
Vaccinating secondary school age-children aged 11–13 
years of age alone did not result in a significant reduc-
tion in cumulative incidence/positivity for any surveil-
lance indicator when comparing secondary school 
pilot areas to non-pilot areas, for both targeted and 
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non-targeted age groups, with the exception of emer-
gency department attendances in the target age group 
and confirmed influenza hospital admissions in adults 
(Table 2).
Through determining cumulative risk difference 
between pilot and non-pilot areas by age group and 
indicator, it is estimated that 16 primary school age 
children needed to be vaccinated to prevent one GP 
ILI consultation in the pilot population; 317 children to 
prevent one confirmed influenza hospitalisation and 
2,205 children to prevent one confirmed influenza ICU/
HDU admission.
Discussion
This study assesses the uptake and evaluates the 
impact of the second season of the new UK LAIV pro-
gramme for children in England. Piloting the LAIV pro-
gramme in primary and now secondary school age 
children in the 2014/15 influenza season, resulted in 
similar or higher levels of uptake compared with the 
first. Pilot areas that chose to deliver the programme 
through school settings achieved higher uptake than 
those delivered through community settings, such as 
pharmacies. Despite the circulation of drifted A(H3N2) 
and B influenza strains, our results demonstrate that 
vaccinating children of primary school age resulted in 
a significant reduction in incidence for a range of sur-
veillance indicators. This effect was evident in targeted 
and non-targeted age groups compared with popula-
tions where primary school age children were not vac-
cinated. The size of the effect was less for more severe 
endpoints, in particular excess mortality. Vaccination 
of secondary school age children alone (11–13 years of 
age) failed to show conclusive evidence of such reduc-
tions in disease incidence in either targeted or non-
targeted age-groups.
The study has a series of strengths; it builds on 
approaches developed in 2013/14 to evaluate the 
uptake and impact of the newly established childhood 
LAIV programme, population-level data sources are 
used and the findings are consistent with the 2013/14 
findings in terms of uptake, and an impact seen across 
a range of indicators when primary school children only 
were targeted [6]. There are, however, also some limita-
tions. Firstly, examination of historical data suggests 
some caution is needed. The apparent effect sizes 
should not be overestimated. Our results suggest that 
the level of activity was lower for some indicators in the 
previous season (2012/13) in primary school age pilot 
areas, although the observation was less apparent in 
the season before that (2011/12) (Figure 6). Secondly, 
uptake in two to four year-olds in primary school age 
only pilot areas was slightly different compared with 
non-pilot areas, which has the potential to affect effect 
sizes.
The uptake achieved in school age children this season 
builds on that reached in 2013/14, with coverage now 
in excess of 50% in almost all pilot areas delivering 
the programme through a school-based approach 
(for either primary or secondary school age children). 
Earlier modelling work had suggested that at these 
levels of uptake for all school-age children, indirect 
benefits through reduction in population transmission 
of influenza are likely to occur [2]. Our findings also 
highlight the lower uptake among school age children 
achieved in areas deploying non-school based deliv-
ery approaches. This mirrors observations in relation 
to human papillomavirus (HPV) adolescent vaccine 
programmes, where countries using school-based 
delivery models achieved consistently higher uptake 
compared with other approaches [18]. In countries 
such as England, with its very high school attendance 
levels, there seem to be clear advantages to this deliv-
ery approach for a paediatric influenza vaccine pro-
gramme for children of school age, although there was 
still variation in uptake, particularly in relation to fac-
tors such as deprivation and ethnicity in 2013/14 [19]. 
Further work is still required to refine the optimal deliv-
ery model, particularly from an equity and efficiency 
perspective.
The finding that vaccinating children of primary school 
age, in addition to the pre-school vaccination pro-
gramme, led to reductions in disease incidence in both 
targeted and non-targeted age groups for a range of 
influenza indicators builds on observations from the 
first year of the programme when only primary school 
age children were vaccinated in pilot areas [6]. This 
season we observed in these areas decreases in influ-
enza disease not only in the primary school age chil-
dren themselves, but also indirectly in children under 
five years of age, where the burden of influenza is rec-
ognised to be highest, together with smaller indirect 
reductions in adults, where influenza disease burden 
is also high (in particular in the elderly and clinical 
risk groups). The indirect impact of vaccinating primary 
school age children under five years old is over and 
above any direct impact that might have been due to 
the pre-school LAIV programme itself which operated 
across the whole of England in both pilot and non-pilot 
areas. These indirect reductions were consistently seen 
for primary care consultations (for both clinical and viro-
logical end-points) and laboratory confirmed hospitali-
sations and ICU/HDU admissions. As seen in 2013/14 
though, the effect sizes became less as the end-points 
become more severe. These findings are supported by 
publications from elsewhere [3-5], including a recent 
article by Tran et al. showing that vaccination of school 
age children (with ca 50% uptake) led to large reduc-
tions in ILI emergency department visits across all ages 
in the local community [20]. In addition, the differential 
roll-out of the LAIV programme across the countries of 
the UK, with Scotland and Northern Ireland vaccinat-
ing primary school age children and Wales secondary 
school age children in 2014/15 has shown some early 
encouraging signs in relation to reductions in primary 
care consultations for those countries vaccinating 
primary school age children. This will provide further 
important opportunities to understand the population 
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level impacts of the universal paediatric influenza vac-
cination programme [8].
The 2014/15 season was characterised by significant 
excess all-cause mortality across Europe, particularly 
in the elderly, an observation consistent with the cir-
culation of influenza A(H3N2) [8]. Although there was 
reduction in respiratory excess mortality in primary 
compared with non-pilot areas, we found no evidence 
of a significant reduction in excess all-cause mortality. 
The reduction in excess respiratory mortality in those 
areas where primary school age children were vacci-
nated is encouraging, though the reasons for the lack of 
visibility of an indirect effect for excess all-cause mor-
tality, which is a more non-specific indicator, are not 
totally clear, but could well be linked to lack of study 
power and is consistent with the smaller reductions we 
saw for the more severe end-points in the older age-
groups. Further work is planned to understand these 
differences, as this is where much of the health eco-
nomic benefits of a school-age influenza vaccination 
programme will be derived [2].
Despite looking at a range of indicators, we were una-
ble to demonstrate evidence that vaccinating a cohort 
of children of secondary school age (albeit the first two 
years of secondary school) alone led to any consist-
ent reduction in disease incidence in either targeted or 
non-targeted age groups in pilot areas. Although other 
studies have shown reductions in rates of respiratory 
illness in secondary school populations that under-
take universal vaccination [21], no other studies, to 
our knowledge have shown population level benefits 
of vaccinating secondary school age children alone, 
although it is important to note that only two cohorts 
of secondary school age pupils were offered vaccina-
tion in the present pilot.
It is also important to note that the reductions we 
observed occurred in a season in which an antigeni-
cally and genetically drifted A(H3N2) strain was the 
predominant circulating strain [8,9], that had earlier 
resulted in low overall vaccine effectiveness against 
influenza A(H3N2), albeit with some evidence of effec-
tiveness for LAIV in children [22]. Of further note, is that 
the dominant circulating influenza B viruses at the end 
of the 2014/15 season also showed evidence of drift 
from the influenza B/Yamagata lineage vaccine strain 
[8]. These population-level impact findings of LAIV 
vaccination of school-age children suggests LAIV may 
have cross-protective effects against drifted strains, 
as reported previously [23].
In conclusion, our findings support the on-going roll out 
of the national LAIV programme for children of primary 
school age. The added benefit of vaccinating second-
ary school age children needs further careful consid-
eration. Further work will need to continue to evaluate 
the impact of the LAIV programme against a range of 
end-points, in particular mortality related end-points.
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